

Supplementary Table S1: The relationship between pre-treatment proteins, clinical parameters and OS using the log-rank test

		Mean ^a	
		Estimate	Std. Error
GHRH-R	Low intensity	112.556	4.154
	High intensity	75.781	4.325
	Log-rank (Mantel-Cox) Sig.: 0.000		
Hsp90	Low intensity	104.722	4.372
	High intensity	79.644	4.639
	Log-rank (Mantel-Cox) Sig.: 0.004		
p-Akt	Low intensity	113.077	2.828
	High intensity	80.048	4.304
	Log-rank (Mantel-Cox) Sig.: 0.001		
SOUL	Low intensity	86.237	6.098
	High intensity	88.563	4.460
	Log-rank (Mantel-Cox) Sig.: 0,661		
HSP 16.2	Low intensity	89.920	4.831
	High intensity	85.655	5.308
	Log-rank (Mantel-Cox) Sig.: 0,975		
Responses	TRG(3,4,5)	80.351	5.199
	TRG(1,2)	95.280	4,849
	Log-rank (Mantel-Cox) Sig.: 0.029		
	upper	100.063	4.599

Tumor localization	middle	75.256	5.957
	lower	92.529	6.899
	Log Rank (Mantel-Cox) Sig.: 0.015		
Gender	male	82.255	4.921
	female	93.704	5.165
	Log Rank (Mantel-Cox) Sig.: 0.057		
Time to surgery	<= 7 week	88.508	4.888
	> 7 week	85.636	5.450
	Log Rank (Mantel-Cox) Sig.: 0.568		

^a Estimation is limited to the largest survival time if it is censored

Supplementary material to the following manuscript:

Expression levels of GHRH-Receptor, pAkt and Hsp90 predict 10-year overall survival in patients with locally advanced rectal cancer